checkAd
    Startseite > Aktien > Lyra Therapeutics > Nachrichten
    Lyra Therapeutics Aktie
    4,7200
     
    USD
    -8,70 %
    -0,4500 USD
    Letzter Kurs 27.04.24 Nasdaq
    4,7200
     
    USD
    500 STK
    Geldkurs 26.04.24
    4,7400
     
    USD
    1.200 STK
    Briefkurs 26.04.24
    ISIN: US55234L1052 · WKN: A2P36P · SYM: LYRA · USA

    Neueste Nachrichten

    Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    26.04.24 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    21.03.24 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    01.03.24 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics to Participate in Upcoming Investor Conferences
    07.11.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
    16.10.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
    12.09.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics to Participate in Upcoming Investor Conferences
    06.09.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
    29.08.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    08.08.23 · globenewswire · Lyra Therapeutics
    Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
    13.07.23 · globenewswire · Lyra Therapeutics
    Lyra: +76% für NBC-Mitglieder – wohin geht die Reise?
    26.06.23 · Sharedeals · Lyra Therapeutics
    Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    02.06.23 · globenewswire · Lyra Therapeutics